<?xml version='1.0' encoding='utf-8'?>
<document id="27052654"><sentence text="Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study."><entity charOffset="23-28" id="DDI-PubMed.27052654.s1.e0" text="T-DM1" /><entity charOffset="35-44" id="DDI-PubMed.27052654.s1.e1" text="docetaxel" /><entity charOffset="61-71" id="DDI-PubMed.27052654.s1.e2" text="pertuzumab" /><pair ddi="false" e1="DDI-PubMed.27052654.s1.e0" e2="DDI-PubMed.27052654.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s1.e0" e2="DDI-PubMed.27052654.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27052654.s1.e0" e2="DDI-PubMed.27052654.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27052654.s1.e1" e2="DDI-PubMed.27052654.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27052654.s1.e1" e2="DDI-PubMed.27052654.s1.e2" /></sentence><sentence text="Trastuzumab emtansine (T-DM1) exhibited enhanced antitumor activity when combined with docetaxel or pertuzumab in preclinical studies"><entity charOffset="23-28" id="DDI-PubMed.27052654.s2.e0" text="T-DM1" /><entity charOffset="87-96" id="DDI-PubMed.27052654.s2.e1" text="docetaxel" /><entity charOffset="100-110" id="DDI-PubMed.27052654.s2.e2" text="pertuzumab" /><pair ddi="false" e1="DDI-PubMed.27052654.s2.e0" e2="DDI-PubMed.27052654.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s2.e0" e2="DDI-PubMed.27052654.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27052654.s2.e0" e2="DDI-PubMed.27052654.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27052654.s2.e1" e2="DDI-PubMed.27052654.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27052654.s2.e1" e2="DDI-PubMed.27052654.s2.e2" /></sentence><sentence text=" This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and T-DM1 + docetaxel ± pertuzumab in patients with HER2-positive locally advanced breast cancer (LABC)"><entity charOffset="53-70" id="DDI-PubMed.27052654.s3.e0" text="T-DM1 + docetaxel" /><entity charOffset="180-196" id="DDI-PubMed.27052654.s3.e1" text="T-DM1" /><pair ddi="false" e1="DDI-PubMed.27052654.s3.e0" e2="DDI-PubMed.27052654.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s3.e0" e2="DDI-PubMed.27052654.s3.e1" /></sentence><sentence text="" /><sentence text="Phase Ib (part 1) explored dose escalation, with T-DM1 + docetaxel administered for greater than or equal to six cycles in patients with MBC"><entity charOffset="49-66" id="DDI-PubMed.27052654.s5.e0" text="T-DM1 + docetaxel" /></sentence><sentence text=" Phase Ib (part 2) began with the maximum tolerated dose (MTD) identified in part 1" /><sentence text=" Patients with LABC were administered less than or equal to six cycles of T-DM1 + docetaxel or T-DM1 + docetaxel + pertuzumab"><entity charOffset="74-91" id="DDI-PubMed.27052654.s7.e0" text="T-DM1 + docetaxel" /><entity charOffset="95-125" id="DDI-PubMed.27052654.s7.e1" text="T-DM1 + docetaxel + pertuzumab" /><pair ddi="false" e1="DDI-PubMed.27052654.s7.e0" e2="DDI-PubMed.27052654.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s7.e0" e2="DDI-PubMed.27052654.s7.e1" /></sentence><sentence text=" Phase IIa explored the MTDs identified in phase Ib" /><sentence text="" /><sentence text="Administered with T-DM1 (3"><entity charOffset="18-23" id="DDI-PubMed.27052654.s10.e0" text="T-DM1" /></sentence><sentence text="6 mg/kg), the docetaxel MTD was 60 mg/m(2) in MBC"><entity charOffset="14-23" id="DDI-PubMed.27052654.s11.e0" text="docetaxel" /></sentence><sentence text=" In LABC, the MTD was 100 mg/m(2) docetaxel in combination with T-DM1 (3"><entity charOffset="34-43" id="DDI-PubMed.27052654.s12.e0" text="docetaxel" /><entity charOffset="64-69" id="DDI-PubMed.27052654.s12.e1" text="T-DM1" /><pair ddi="false" e1="DDI-PubMed.27052654.s12.e0" e2="DDI-PubMed.27052654.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s12.e0" e2="DDI-PubMed.27052654.s12.e1" /></sentence><sentence text="6 mg/kg), given with granulocyte colony-stimulating factor (G-CSF)" /><sentence text=" Administered with T-DM1 (3"><entity charOffset="19-24" id="DDI-PubMed.27052654.s14.e0" text="T-DM1" /></sentence><sentence text="6 mg/kg) + pertuzumab (840 mg, cycle 1; 420 mg, subsequent cycles), the docetaxel MTD in LABC was 75 mg/m(2) with G-CSF support"><entity charOffset="72-81" id="DDI-PubMed.27052654.s15.e0" text="docetaxel" /><entity charOffset="89-93" id="DDI-PubMed.27052654.s15.e1" text="LABC" /><pair ddi="false" e1="DDI-PubMed.27052654.s15.e0" e2="DDI-PubMed.27052654.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s15.e0" e2="DDI-PubMed.27052654.s15.e1" /></sentence><sentence text=" Neutropenia was the most common grade 3-4 adverse event (AE; MBC, 72% and LABC, 29%)"><entity charOffset="75-78" id="DDI-PubMed.27052654.s16.e0" text="LABC" /></sentence><sentence text=" In total, 48% (12/25) of MBC patients and 47% (34/73) of LABC patients experienced AEs requiring dose modification"><entity charOffset="58-61" id="DDI-PubMed.27052654.s17.e0" text="LABC" /></sentence><sentence text=" In MBC (median prior systemic agents = 5), the objective response rate was 80" /><sentence text="0% (20/25; 95% confidence interval [CI] 59" /><sentence text="3-93" /><sentence text="2) and the median progression-free survival was 13" /><sentence text="8 months (range, 1" /><sentence text="6-33" /><sentence text="5)" /><sentence text=" The pathologic complete response (ypT0/is, ypN0) rate in LABC was 60"><entity charOffset="58-61" id="DDI-PubMed.27052654.s25.e0" text="LABC" /></sentence><sentence text="3% (44/73; 95% CI 48" /><sentence text="1-71" /><sentence text="5)" /><sentence text=" Pharmacokinetic analyses indicated a low risk of drug-drug interaction between T-DM1 and docetaxel"><entity charOffset="90-99" id="DDI-PubMed.27052654.s29.e0" text="docetaxel" /><entity charOffset="80-88" id="DDI-PubMed.27052654.s29.e1" text="T-DM1" /><pair ddi="false" e1="DDI-PubMed.27052654.s29.e1" e2="DDI-PubMed.27052654.s29.e1" /><pair ddi="false" e1="DDI-PubMed.27052654.s29.e1" e2="DDI-PubMed.27052654.s29.e0" /></sentence><sentence text="" /><sentence text="T-DM1 combined with docetaxel ± pertuzumab appeared efficacious in MBC or LABC; however, nearly half of patients experienced AEs requiring dose reductions with these T-DM1 combinations"><entity charOffset="20-29" id="DDI-PubMed.27052654.s31.e0" text="docetaxel" /><entity charOffset="0-8" id="DDI-PubMed.27052654.s31.e1" text="T-DM1" /><entity charOffset="166-174" id="DDI-PubMed.27052654.s31.e2" text="T-DM1" /><entity charOffset="74-82" id="DDI-PubMed.27052654.s31.e3" text="LABC" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e1" e2="DDI-PubMed.27052654.s31.e1" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e1" e2="DDI-PubMed.27052654.s31.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e1" e2="DDI-PubMed.27052654.s31.e3" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e1" e2="DDI-PubMed.27052654.s31.e2" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e0" e2="DDI-PubMed.27052654.s31.e0" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e0" e2="DDI-PubMed.27052654.s31.e3" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e0" e2="DDI-PubMed.27052654.s31.e2" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e3" e2="DDI-PubMed.27052654.s31.e3" /><pair ddi="false" e1="DDI-PubMed.27052654.s31.e3" e2="DDI-PubMed.27052654.s31.e2" /></sentence><sentence text="" /><sentence text="NCT00934856" /><sentence text="" /></document>